Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma†
Version of Record online: 26 JAN 2007
Copyright © 2007 American Association for the Study of Liver Diseases
Volume 45, Issue 2, pages 277–285, February 2007
How to Cite
Pollicino, T., Raffa, G., Costantino, L., Lisa, A., Campello, C., Squadrito, G., Levrero, M. and Raimondo, G. (2007), Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology, 45: 277–285. doi: 10.1002/hep.21529
Potential conflict of interest: Nothing to report.
- Issue online: 26 JAN 2007
- Version of Record online: 26 JAN 2007
- Manuscript Accepted: 4 NOV 2006
- Manuscript Received: 18 AUG 2006
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- Italian Ministero dell'Istruzione Università e Ricerca (MIUR)
- Fondi per gli Investimenti per la Ricerca di Base (FIRB)
Supplementary material for this article can be found on the H EPATOLOGY website ( http://interscience.wiley.com/jpages/0270-9139/suppmat/index.html ).
|jws-hep.21529.fig1.pdf||39K||Supplemental Figure 1 - Schematic drawing of occult HBV full-length PCR amplification. The two subgenomic fragments, ?Fragment A? and ?Fragment B?, were amplified by nested PCR with two different combinations of primers and ligated by using the AvrII unique restriction site of HBV (nucleotide position 179).|
|jws-hep.21529.fig2.pdf||9K||Supplemental Figure 2 - Schematic representation showing mutations affecting the preS1 promoter in the representative HBV isolates of the 17 studied patients. Nucleotide coordinates for the genotype D are provided. Binding sites for the liver-specific transcription factors HNF-1 and HNF-3 and sites for interaction with TBP and Sp1 are indicated.|
|jws-hep.21529.fig3.pdf||10K||Supplemental Figure 3 - Schematic representation of mutations observed in the S promoter of the representative HBV isolates from the 17 studied patients. Numbering is according to genotype D. The NF-Y motif and sites for interaction with transcription factors NF1 and SP1 are shown.|
|jws-hep.21529.fig4.pdf||57K||Supplemental Figure 4 - Schematic representation of mutations observed in the enhancer I/X promoter complex of the representative HBV isolates form the 17 studied patients. Numbering is according to genotype D. Sites for interaction with specific transcription factors are indicated.|
|jws-hep.21529.fig5.pdf||14K||Supplemental Figure 5 - Schematic representation of mutations observed in the core promoter/enhancer II complex of the representative HBV isolates form the 17 studied patients. Numbering is according to genotype D. The TATA box-like sequences and transcription initiation sites of the precore and pregenomic RNA are indicated. Transcription factor binding sites are indicated as a schematic footprint.|
|jws-hep.21529.tbl1.pdf||69K||Supplementary Table 1 . Oligonucleotides used as PCR and Sequencing Primers|
|jws-hep.21529.pdf||109K||Supporting Information file jws-hep.21529.pdf|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.